Eli Lilly and Co (NYSE:LLY) saw some unusual options trading activity on Tuesday. Stock investors purchased 25,554 call options on the stock. This is an increase of 835% compared to the typical daily volume of 2,733 call options.
In related news, SVP Jeffrey N. Simmons sold 9,625 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.12, for a total transaction of $780,780.00. Following the transaction, the senior vice president now directly owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Donald A. Zakrowski sold 900 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the transaction, the insider now directly owns 4,130 shares in the company, valued at $334,901.70. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,261 shares of company stock worth $987,485. 0.20% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in LLY. Janus Henderson Group PLC grew its holdings in shares of Eli Lilly and by 7,093.5% during the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after buying an additional 9,223,251 shares during the last quarter. Dodge & Cox grew its holdings in shares of Eli Lilly and by 22,094.9% during the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after buying an additional 5,964,955 shares during the last quarter. Renaissance Technologies LLC lifted its position in Eli Lilly and by 91.1% during the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after purchasing an additional 2,714,505 shares during the period. Bank of Montreal Can lifted its position in Eli Lilly and by 85.4% during the fourth quarter. Bank of Montreal Can now owns 4,631,241 shares of the company’s stock valued at $391,156,000 after purchasing an additional 2,133,606 shares during the period. Finally, Investec Asset Management LTD acquired a new position in Eli Lilly and during the fourth quarter valued at $163,570,000. 77.58% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Eli Lilly and (NYSE:LLY) opened at $79.15 on Wednesday. The firm has a market cap of $86,596.06, a price-to-earnings ratio of 18.47, a PEG ratio of 1.47 and a beta of 0.28. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85. Eli Lilly and has a 1-year low of $73.69 and a 1-year high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.95 earnings per share. analysts predict that Eli Lilly and will post 4.87 EPS for the current fiscal year.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.